Eikon picks up $517.8 million in Series B funding and expands executive team

Eikon Therapeutics, a pioneer in the application of live-cell super-resolution microscopy to drug discovery, has closed a $517.8 million Series B financing. Since its founding two years ago, Eikon Therapeutics has raised more than $668 million to advance its mission of inventing new therapies that address grievous illness.

“Through the integration of advanced engineering and high-performance computing, alongside more traditional molecular biology and medicinal chemistry, Eikon is developing a battery of innovative tools for biological exploration,” said Dr Roger Perlmutter, chief executive and chairman of Eikon Therapeutics, who joined the company in May last year from Merck & Co (NYSE: MRK), where he was president of Merck Research Laboratories.

New investors participating in the Series B financing include funds and accounts advised by T Rowe Price Associates, Canada Pension Plan Investment Board (CPP Investments), EcoR1 Capital, UC Investments (Office of the Chief Investment Officer of the Regents of the University of California), ADIA, a wholly owned subsidiary of the Abu Dhabi Investment Authority, StepStone Group, Soros Capital, Schroders Capital, Harel Insurance, General Catalyst, E15 VC, Hartford HealthCare Endowment, and AME Cloud Ventures. The financing also included participation from the company’s Series A investors: The Column Group, Foresite Capital, Innovation Endeavors, Lux Capital, and Horizons Ventures.